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BACKGROUND: This study investigates obesity and comorbidity in Black and White women with early breast cancer (stages I-III) and 
their potential impact on treatment decisions for patients with hormone receptor–positive (HR+)/human epidermal growth factor recep-
tor 2–negative (HER2–) tumors. METHODS: In this retrospective chart review, comparisons of frequencies for Black and White patients 
were calculated with the Fisher exact test. Log binomial regression was used to estimate prevalence ratios (PRs) with 95% confidence 
intervals for total and individual comorbidities, and multivariable modeling was used to estimate PRs adjusted for age and body mass 
index (BMI). RESULTS: In a sample of 548 patients, 26% were Black, and 74% were White. Sixty-two percent of Black patients and 
32% of White patients were obese (BMI ≥ 30 kg/m2; P < .0001). Seventy-five percent of Black patients and 87% of White patients had
HR+ tumors (P = .001). Significant intergroup differences were seen for 2 or more total comorbidities (62% of Blacks vs 47% of Whites;
P = .001), 2 or more obesity-related comorbidities (33% vs 10%; P < .0001), hypertension (60% vs 32%; P < .0001), diabetes mellitus (23% 
vs 6%; P < .0001), hypercholesterolemia or hyperlipidemia (28% vs 18%; P = .02), and hypothyroidism (4% vs 11%; P = .012). In women with 
HR+/HER2– tumors, there were no intergroup differences in treatment decisions regarding the type of surgery, chemotherapy regimen,
radiation, or endocrine treatment despite significant differences in the prevalence of obesity and comorbidities. CONCLUSIONS: This 
study documents significant disparities between Black and White women with early breast cancer with regard to high rates of obesity, 
overall comorbidities, and obesity-related comorbidities, and it highlights the prevalence of competing risks that may complicate out-
comes in breast cancer. Cancer 2021;127:922-930. © 2020 American Cancer Society. 
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INTRODUCTION
Obesity rates started rising notably in the United States in the 1980s, and the Black community and especially Black 
women were disproportionately affected.1 At the same time, rates of breast cancer increased rapidly, especially for hor-
mone receptor–positive (HR+) disease.2 A high body mass index (BMI) is a known risk factor for HR+ breast cancer 
in postmenopausal women3 and thereby contributes to rising breast cancer incidence trends along with lower parity and 
increased detection through mammography screening.4 Notably, rates of HR+ breast cancer increased more rapidly in 
Black women than White women, and this led to a convergence in overall breast cancer incidence rates.5
At the same time that breast cancer incidence rates were converging between Black and White women, mortality 
trends were moving in the opposite direction. In the mid-1970s, breast cancer mortality rates were about the same for 
Black and White women; however, by 2015, mortality rates had diverged dramatically to the point where they are now 
40% higher for Black women than White women.6 Even with highly treatable stage I to III HR+/human epidermal 
growth factor receptor 2–negative (HER2–) cancers, Black women have a 31% higher chance of dying in comparison 
with White women.7
Many factors contribute to survival disparities in women with breast cancer.8-18 By some estimates, tumor biology, treat-
ment, sociodemographics, and neighborhood factors combined account for 50% of the Black-White disparity.13,19 Another 
study found that insurance coverage alone explained 50% of the survival disparity.20 These findings are illuminating but leave 
much to be explained by other factors. Specifically with regard to overall survival, the impact of both obesity and comorbid-
ities on breast cancer outcomes is an important consideration. For example, obesity has been associated with underdosing of 
women receiving chemotherapy for early breast cancer,21,22 and comorbidities can influence the receipt of guideline-concordant 
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treatment23,24 and in turn affect prognosis and survival.25,26 
Tammemagi et al27 reported worse competing cause sur-
vival in Black women versus White women with breast 
cancer (hazard ratio, 1.27; 95% CI, 1.00-1.63), and they 
concluded that “effective control of comorbidity in breast 
cancer patients should help improve life expectancy and 
lead to a reduction in survival disparities.”
As advances in treatment options continue to im-
prove outcomes for women with early breast cancer, 
women with highly treatable early-stage HR+ tumors are 
more likely to die of causes other than their early breast 
cancer.28 A recent study showed that among women with 
breast cancer who died 10 or more years after their diag-
nosis, 60.9% died of noncancer causes, whereas 23.6% 
and 15.5% died of breast cancer and other cancers, re-
spectively.29 Even within the 5 to 10 years after the diag-
nosis, 48.4% died of noncancer causes, and regardless of 
the time since diagnosis, Black women had higher stan-
dardized mortality ratios for individual noncancer causes 
of death.29 Noncancer causes include chronic diseases 
that, like cancer, are associated with advancing age, and 
many are obesity-related: heart disease, stroke, diabetes 
mellitus, kidney disease, and hypertension.30
Notably, among women with HR+ breast cancer, 
the hazard ratio for breast cancer death was 4.39 (95% 
CI, 1.76-10.9; P = .001) for Black women versus White 
women after adjustments for stage, grade, and treat-
ment.31 In that study, the proportion of women with a 
BMI > 30 kg/m2 was 48% for Black women and 27% for 
White women (P < .0001), and the conclusion was that 
BMI was associated with breast cancer death at 5 years.31 
Further evidence of the potential impact of unhealthy 
weight was seen in a meta-analysis showing that among 
women with HR+ tumors, the pooled hazard ratio for 
overall survival was 1.31 (95% CI, 1.17-1.46) for women 
with obesity versus women without obesity.32
In the current study, we investigate prevalence rates 
for obesity and comorbidities in Black and White women 
with early breast cancer (stages I-III) seen in current clinical 
practice. We estimate the prevalence ratios (PRs) for indi-
vidual comorbidities, total comorbidities, and obesity-re-
lated comorbidities by race with adjustments for age and 
BMI. We also investigate whether obesity, age, and comor-
bidities at diagnosis affect treatment decisions in women 
with HR+/HER2– tumors, which account for 69% of 
new cases in non-Hispanic White women and 55% in 
non-Hispanic Black women in the United States6 and have 
the greatest disparity in outcomes.33 Our hypothesis is 
that to the extent that Black and White women differ with 
regard to obesity, age, and comorbidities at breast cancer 
diagnosis, this may differentially affect treatment decisions 
in Black and White women with HR+/HER2– tumors.
MATERIALS AND METHODS
Breast Cancer Sample
This is a retrospective chart review of women seen in 
breast cancer clinics at a single institution, as described 
in previous studies.34 To build the database, the electronic 
medical record was reviewed for women aged 18 years or 
older with stage I to III breast cancer who had no evidence 
of breast cancer recurrence, progression, or metastasis and 
had weight data for 2 years after their primary treatment. 
To ensure sufficient numbers of analyzable women with 
triple-negative or HR–/HER2+ tumors, we also included 
women enrolled in the Neoadjuvant Database of the 
University of North Carolina Lineberger Comprehensive 
Cancer Center (LCCC9815, IRB 01-1154) who met the 
inclusion criteria. The years of diagnosis were 1992-2004 
(8%), 2005-2009 (23%), and 2010-2014 (69%). Women 
aged 50 years or older at diagnosis were assumed to be 
postmenopausal. The study was approved by the institu-
tional review board of the University of North Carolina at 
Chapel Hill (IRB 15-1523).
Measures
Data pertaining to participant demographics, breast can-
cer diagnoses and treatments, and comorbidities at diag-
nosis were extracted from the electronic medical record 
(Epic@UNC). Age was dichotomized at 65 years or older, 
which is the age of Medicare eligibility (which could af-
fect insurance coverage). Weight and height measures at 
breast cancer diagnosis were taken by nursing staff during 
routine clinic visits and were recorded in the electronic 
medical record; in our analysis, BMI was dichotomized 
at ≥30 kg/m2, which is the cut point for obesity. The 16 
comorbidities of interest are shown in Table 1. Obesity-
related comorbidities were defined as hypertension, heart 
disease, and diabetes.
Statistical Considerations
Descriptive statistics were used to characterize patient 
demographics, breast cancer diagnoses and treatments, 
and comorbidities at diagnosis. Comparisons of frequen-
cies for Black and White subjects were calculated with 
the Fisher exact test. Log binomial regression was used 
to estimate PRs with 95% confidence intervals (CIs) for 
individual comorbidities. Multivariable modeling was 
used to estimate adjusted PRs while we controlled for age 
and BMI. All analyses were performed with SAS statistical 
software (version 9.4; SAS, Cary, North Carolina).
RESULTS
In a sample of 548 women, 26% were Black, and 74% 
were White; the mean age was 55 years (range, 25-83 
years) for Black women and 57 years (range, 24-92 
years) for White women (Table 1). Sixty-two percent 
of Black patients and 32% of White patients were 
obese (P < .0001). Sixty-five percent of Black women 
and 74% of White women had HR+/HER2– tumors 
(P = .004).
Comorbidities
Figure 1 presents rates of comorbidities in Black and 
White patients (full sample). Statistically significant dif-
ferences were seen for 2 or more total comorbidities at 
TABLE 1. Study Participants (N = 548)
Blacks (n = 144 [26%]) Whites (n = 404 [74%]) P
Demographics
Age, mean (SD) [range], y 55 (11.6) [25-83] 57 (12.5) [24-92]
Age, No. (%) .01
<65 y 118 (82) 289 (72)
≥65 y 26 (18) 115 (28)
BMI, No. (%) <.0001
<25 kg/m2 21 (16) 149 (38)
25-30 kg/m2 (overweight) 30 (22) 119 (30)
≥30 kg/m2 (obese) 83 (62) 123 (32)
Comorbidities at breast cancer diagnosis
Total No. of comorbidities, No. (%) .003
<2 54 (38) 215 (53)
2-4 78 (54) 171 (42)
>4 12 (9) 18 (5)
Obesity-related comorbidities, mean (SD) [range]a 1.18 (0.96) [0-4] 0.60 (0.80) [0-4] <.0001
Most prevalent comorbidities at breast cancer 
diagnosis, No. (%)
Hypertension 86 (60) 131 (32) <.0001
Hypercholesterolemia or hyperlipidemia 40 (28) 74 (18) .02
Diabetes mellitus 33 (23) 25 (6) <.0001
Stomach or intestinal disorders 31 (22) 62 (15) .09
Arthritis or rheumatism 23 (16) 68 (17) .90
Depression 20 (14) 72 (18) .30
Mental health (other than depression) 10 (7) 48 (12) .15
Heart disease 8 (6) 11 (3) .12
Liver or kidney disease 5 (4) 11 (3) .58
Hypothyroidism 6 (4) 45 (11) .01
Circulation disorders 4 (3) 7 (2) .49
Glaucoma 4 (3) 9 (2) .75
Emphysema 1 (1) 9 (2) .47
Lymphedema 1 (1) 3 (1) 1.0
Osteoporosis 1 (1) 13 (3) .13
Stroke 2 (1) 12 (3) .38
Breast cancer diagnosis, No. (%)
Breast cancer stage .96
I 41 (30) 138 (32)
II 60 (43) 190 (44)
III 37 (26) 101 (23
Tumor grade .08
1 22 (16) 88 (22)
2 48 (36) 156 (41)
3 65 (48) 141 (37)
HR (ER/PR) .001
Negative 36 (25) 53 (13)
Positive 106 (75) 345 (87)
HER2 .59
Negative 121 (86) 331 (84)
Positive 20 (14) 65 (16)
Phenotype .004
HR–/HER2– 30 (21) 38 (10)
HR–/HER2+ 7 (5) 15 (4)
HR+/HER2– 91 (65) 293 (74)
HR+/HER2+ 13 (9) 50 (13)
Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PR, progesterone receptor.
aObesity-related comorbidities included hypertension, heart disease, and diabetes mellitus.
P values in bold print are significant at P < .05.
diagnosis (62% of Blacks vs 47% of Whites; P = .001), 
2 or more obesity-related comorbidities (33% vs 10%;  
P < .0001), hypertension (60% vs 32%; P < .0001), 
diabetes (23% vs 6%; P < .0001), hypercholesterolemia 
or hyperlipidemia (28% vs 18%; P = .02), and hypo-
thyroidism (4% vs 11%; P = .012). There were no sig-
nificant differences between Black and White patients 
for arthritis (overall 17%), stomach/intestinal disorders 
(17%), depression (17%), other mental health disorders 
(11%), heart disease (9%), osteoporosis (3%), kidney or 
liver disease (3%), stroke (3%), emphysema (2%), glau-
coma (2%), circulation problems (2%), or lymphedema 
(1%). In a multivariable analysis adjusted for age and 
BMI (Table 2), Black women had higher frequencies of 
hypertension (PR, 1.45; 95% CI, 1.19-1.75; P = .0002), 
hypercholesterolemia or hyperlipidemia (PR, 1.43; 95% 
CI, 1.01-2.02; P = .044), and diabetes mellitus (PR, 
1.44; 95% CI, 1.02-2.03; P < .0001).
Treatment Decisions: HR+/HER2– Patients
In light of observed disparities in comorbidities at  
diagnosis and disparities in outcomes,33 we investi-
gated whether preexisting conditions (obesity and 
comorbidities) at diagnosis influenced treatment deci-
sions in patients with HR+/HER2– tumors (Table 3). 
We focused our analysis on this subtype because there 
can be some flexibility in treatment plans in compari-
son with patients with other subtypes, for whom chem-
otherapy is the sole option (eg, triple-negative tumors), 
endocrine treatment is not an option (HR– tumors), 
or anti-HER2 therapy is essential (HER2+ tumors). 
Patients with the HR+/HER2– subtype composed 
72% of our sample: 65% of Black patients and 74% 
of White patients. Within this subtype, there were 
between-group differences in age (Black patients were 
younger [P = .03]), BMI (Black patients had a higher 
proportion with obesity [P < .0001]), comorbidities 
(Black patients had more total comorbidities [P = .05] 
and obesity-related comorbidities [P < .0001]), and 
individual comorbidities. There were no intergroup 
differences in breast cancer stage (P = .95) or grade 
(P = .72). With regard to treatment decisions, there 
were no significant differences between Black and White 
women in the type of surgery (lumpectomy vs mastec-
tomy), chemotherapy timing (neoadjuvant vs adjuvant) 
or type (anthracycline-based vs not anthracycline-
based), receipt of radiation treatment, or endocrine 
treatment.
In a multivariable analysis adjusted for age and 
BMI (Table 4), comorbidity PRs for women with HR+/
HER2– tumors were higher in Black women for 2 or 
more obesity-related comorbidities (PR, 1.95; 95% CI, 
Figure 1. Comorbidities by race (P ≤ .05). The data are shown as percentages.
1.26-3.03; P = .003), hypertension (PR, 1.44; 95% CI, 
1.16-1.78; P = .0009), and diabetes mellitus (PR, 2.97; 
95% CI; 1.59-5.54; P = .0007).
Our sample was too small for similar analyses of 
HR–/HER2+ and HR+/HER2+ patients. We did ana-
lyze the triple-negative patients and found no significant 
differences between Black and White patients with re-
spect to age, BMI, comorbidities, breast cancer stage or 
grade, treatment plan, or treatment-related adverse events 
(data not presented).
DISCUSSION
A high BMI at breast cancer diagnosis is common in 
early-stage breast cancer: approximately 30% of newly 
diagnosed women are overweight (BMI = 25-29 kg/m2), 
and 30% are obese (BMI ≥ 30 kg/m2).35,36 Moreover, 
many gain weight after they have completed their pri-
mary treatment.37,38 Black women generally have a 
higher BMI at breast cancer diagnosis in comparison 
with other racial and ethnic groups.39 In our study, the 
rate at which women had BMIs ≥ 30 kg/m2 was twice 
as high among Black women in comparison with White 
women. We found that racial disparities in the preva-
lence of comorbidities in general and obesity-related 
comorbidities specifically were significant. However, 
in women diagnosed with the most common type of 
early breast cancer (HR+/HER2– tumors), these dis-
parities did not affect surgery, chemotherapy regimen, 
radiation treatment, or endocrine treatment decisions. 
In early breast cancer, patients with the HR+HER2– 
subtype have some discretion in treatment options in 
comparison with patients with other tumor subtypes. 
The decision to offer chemotherapy and the specific 
type of chemotherapy regimen are based on tumor stage 
and phenotype and the treating clinician’s view that the 
patient is “fit” for chemotherapy. This judgment of fit-
ness can include the severity and management of exist-
ing comorbidities. The lack of disparities in treatment 
plans observed in our HR+/HER2– sample may, in 
part, reflect that our patients were from 1 site that is a 
university-affiliated cancer center. It would be impor-
tant and informative to test our findings in a sample of 
patients seen in community-based settings and in larger 
samples of women with other breast cancer subtypes.
Our study corroborates findings from a previous 
study reporting disparities between Black and White 
women with breast cancer in rates of hypertension (48.4% 
vs 21.1%), diabetes mellitus (17.1% vs 3.8%), and car-
diovascular disease (8.4% vs 5.5%).40 Another study 
similarly identified Black-White disparities in the total 
number of comorbidities (2.25 vs 1.83; P < .001), dia-
betes without complications (23% vs 8%; P < .001), and 
hypertension (63% vs 36%; P < .001).27 Importantly, our 
findings pertaining to disparities in comorbidities were 
adjusted for age and BMI, both of which are independent 
predictors of chronic diseases, to identify the independent 
association of race and comorbidities at diagnosis.
To the extent that comorbidities do not influence 
treatment decisions in women with early-stage HR+/
HER2– tumors, as we have reported in our study, they 
will have less of an impact on breast cancer–specific sur-
vival and potentially more of an impact on overall sur-
vival. In the MA.14 study, it was noted that other chronic 
diseases pose joint mortality risks, especially in women 
with a high BMI and an older age (≥70 years).41 In the 
TEAM trial, it was reported that the probability of dying 
of competing causes (49% of deaths) was almost equal 
to that of dying of breast cancer (51%).42 Clinical trials 
have limitations for competing death analysis to the ex-
tent that patients with certain comorbidities are excluded 




Age ≥ 65 y P
Adjusted for BMI 
≥ 30 kg/m2 P
Adjusted for Both 
Age and BMI P
All comorbidities (≥2) 1.34 (1.13-1.57) .0005 1.40 (1.21-1.61) <.0001 1.12 (0.95-1.31) .18 1.11 (0.96-1.28) .15
Obesity-related comor-
bidities (≥2)a
3.21 (2.22-4.6) <.001 3.34 (2.40-4.97) <.0001 2.05 (1.40-2.98) .0002 1.15 (0.96-1.39) .12
Hypertension 1.84 (1.52-2.24) <.0001 1.88 (1.58-2.23) <.0001 1.49 (1.21-1.83) .0002 1.45 (1.19-1.75) .0002
Heart disease 1.52 (1.09-2.12) .01 1.64 (1.18-2.28) .003 1.34 (0.94-1.90) .10 1.44 (1.02-2.03) .23
Hypercholesterolemia 
or hyperlipidemia
1.52 (1.09-2.12) .015 1.64 (1.18-2.28) .003 1.33 (0.93-1.89) .11 1.43 (1.01-2.02 .044
Hypothyroidism 3.70 (2.28-6.01) <.0001 4.20 (2.60-6.80) <.0001 3.03 (1.79-5.13) <.0001 3.34 (1.90-5.86) .39
Diabetes mellitus 1.52 (1.09-2.12) .01 1.64 (1.18-2.28) .003 1.34 (0.94-1.90) .10 1.44 (1.02-2.03) <.0001
Abbreviation: BMI, body mass index.
aObesity-related comorbidities included hypertension, heart disease, and diabetes mellitus.
Values in parentheses are 95% Confidence Intervals.
TABLE 3. Study Participants With HR+/HER2– Breast Cancer (N = 384)
Black (n = 91) White (n = 293) P
Demographics
Age, mean (SD) [range], y 56 (11.9) [25-83] 59 (12.5) [28-92] .03
BMI, No. (%) <.0001
<25 kg/m2 11 (13) 113 (40)
25-30 kg/m2 (overweight) 17 (20) 82 (29)
≥30 kg/m2 (obese) 56 (67) 89 (31)
Comorbidities at breast cancer diagnosis, No. (%)
Total No. of comorbidities .05
<2 35 (38) 148 (51)
≥2 56 (62) 144 (49)
Obesity-related comorbiditiesa <.0001
<2 60 (66) 258 (88)
≥2 31 (34) 34 (12)
Most prevalent comorbidities at breast cancer diagnosis, No. (%)
Hypertension 60 (66) 105 (36) <.0001
Hypercholesterolemia or hyperlipidemia 26 (29) 63 (22) .20
Diabetes mellitus 21 (23) 22 (8) .0002
Stomach or intestinal disorders 22 (24) 43 (15) .05
Arthritis or rheumatism 15 (16) 50 (17) 1.00
Depression 11 (12) 50 (17) .32
Mental health (excluding depression) 4 (4) 30 (10) .09
Heart disease 5 (6) 9 (3) .34
Liver or kidney disease 2 (2) 8 (3) 1.00
Hypothyroidism 4 (4) 32 (11) .06
Circulation problems 2 (2) 7 (2) 1.00
Glaucoma 1 (1) 9 (3) .46
Emphysema 1 (1) 7 (2) .69
Lymphedema 0 (0) 1 (1) 1.00
Osteoarthritis 0 (0) 13 (4) .04
Stroke 1 (1) 11 (4) .31
Breast cancer diagnosis, No. (%)
Breast cancer stage .95
I 34 (39) 105 (37)
II 34 (39) 114 (40)
III 19 (22) 64 (23)
Tumor grade .72
1 21 (24) 73 (27)
2 40 (47) 132 (49)
3 25 (29) 67 (25)
Breast cancer treatment, No. (%)
Surgery .69
None 0 (0) 2 (1)
Lumpectomy 49 (54) 141 (49)
Mastectomy 42 (46) 147 (51)
Radiation .79
No 25 (27) 76 (26)
Yes 66 (72) 215 (74)
Timing of chemotherapy .72
None 43 (47) 126 (43)
Neoadjuvant 21 (23) 79 (27)
Adjuvant 27 (30) 87 (30)
Chemotherapy regimen II .54
Anthracycline-based 30 (71) 114 (77)
Not anthracycline-based 12 (29) 35 (23)
Chemotherapy regimen .85
AC-T 29 (62) 111 (67)
AC-TC 1 (2) 3 (2)
TC 12 (26) 35 (21)
TCH n/a n/a
Any endocrine treatment 91 (100) 288 (99) .58
Specific endocrine treatment .62
Tamoxifen 20 (24) 68 (26)
Aromatase inhibitor only 51 (61) 144 (55)
Tamoxifen followed by aromatase inhibitor 13 (15) 51 (19)
Dose delay: yes 9 (20) 29 (18) .83
Dose reduction: yes 4 (9) 15 (9) 1.00
Early treatment discontinuation: yes 1 (2) 7 (4) 1.00
Abbreviations: AC-T, doxorubicin/cyclophosphamide plus paclitaxel; AC-TC, doxorubicin/cyclophosphamide plus paclitaxel/carboplatin; BMI, body mass index; 
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TC, docetaxel/cyclophosphamide; TCH, docetaxel/carboplatin plus anti-HER2 therapy.
aObesity-related comorbidities included hypertension, heart disease, and diabetes mellitus.
from participation in the trials, and those who partici-
pate are likely to be highly compliant with treatment. In 
a community-based study of women with stage I to IV 
breast cancer seen in a large comprehensive health system 
who were followed for a median of 10 years, it was esti-
mated that 49% of the overall survival disparity and 77% 
of the competing cause death disparity between Black and 
White women were explained by total comorbidities (spe-
cifically diabetes and hypertension).27 In another study, 
hypertension alone was estimated to account for 30% of 
Black-White disparities in overall survival.43 A limitation 
of the latter study is that the breast cancer diagnosis years 
were 1985-1990, that is, before the widespread introduc-
tion of anti-HER2 therapy. In light of treatment regimens 
in current clinical practice and the role of comorbidities in 
the death of women who survive beyond 5 and 10 years,29 
it is time to revisit the impact of individual comorbidities 
on disparities in overall survival, especially in women with 
early HR+/HER2– or HR+/HER2+ breast cancer.
Our study has some limitations. The sample was de-
veloped largely for the purposes of analyzing weight tra-
jectories in women with early breast cancer from diagnosis 
through 2 years after their primary treatment. To avoid 
confounding, the sample excluded women with disease 
recurrence, progression, or metastasis, which could affect 
their weight. This exclusion decision limits the generaliz-
ability of our findings to women who are free of disease 
2 years after their primary treatment. Other than age and 
BMI, we did not have information on factors that may af-
fect obesity-related and other comorbidities, such as diet 
and exercise or genetics. Our sample was drawn from just 
1 institution in 1 state, and this potentially limits the gen-
eralizability to other treatment sites around the country.
A strength of our study is that the sample is large 
and consists of women receiving treatment regimens 
commonly used in current clinical practice. We provide 
prevalence information on 16 comorbidities with adjust-
ments for race, age, and BMI. We also explore the ques-
tion of whether disparities in comorbidities and BMI 
affect treatment decisions, specifically in women with 
HR+/HER2– tumors.
There are 2 important takeaways from our study. 
One is the importance of managing comorbidities in 
women newly diagnosed with early breast cancer to 
reduce their chances of mortality due to competing 
causes.44 We have shown in our study that this is es-
pecially important in Black patients, who have a sig-
nificantly higher prevalence of comorbidities even after 
adjustments for age and obesity. Before their breast can-
cer diagnosis, some women may not have been aware 
of their comorbidities because they were not receiving 
routine care from a primary care physician or other cli-
nician who could have diagnosed the condition. The 
breast cancer diagnosis presents an opportunity to refer 
these patients to appropriate specialists concurrently 
with their cancer treatment. These patients need to un-
derstand that their long-term overall health and survival 
depend as much on the effective management of their 
comorbidities as they do on the successful completion 
of cancer treatment. Further research is needed on how 
to frame this dialogue with patients, with separate and 
focused attention paid to racial and ethnic nuances.
A related takeaway is that patients with excess weight 
at diagnosis and those who experience clinically signifi-
cant weight gain after their primary treatment have added 
risks from obesity and obesity-related diseases that, in 
turn, may affect their survival.45 For these high-risk pa-
tients, there is a need for oncology clinicians to explain 
how an elevated BMI or weight gain, in and of itself, can 
affect their overall health. This conversation can be as 
minimal as the oncology clinician expressing support for 
behavioral change and as much as providing referrals to 




Age ≥ 65 y P
Adjusted for BMI 
≥ 30 kg/m2 P
Adjusted for Both 
Age and BMI P
All comorbidities (≥2) 1.25 (1.02-1.52) .03 1.40 (1.21-1.61) <.0001 1.12 (0.95-1.32) .16 1.08 (0.92-1.27) .36
Obesity-related comor-
bidities (≥2)
2.93 (1.91-4.48) <.0001 3.46 (2.40-4.97) <.0001 2.04 (1.40-2.97) .0002 1.95 (1.26-3.03) .003
Hypertension 1.83 (1.48-2.27) <.0001 1.88 (1.58-2.23) <.0001 1.52 (1.23-1.86) <.0001 1.44 (1.16-1.78) .0009
Heart disease 1.78 (0.61-5.18) .29 2.19 (0.89-5.37) .09 1.64 (0.65-4.12) .30 1.36 (0.45-4.12) .58
Hypercholesterolemia 
or hyperlipidemia
1.32 (0.90-1.96) .16 1.64 (1.18-2.28) .003 1.33 (0.93-1.89) .11 1.16 (0.77-1.75) .47
Hypothyroidism 0.40 (0.15-1.10) .08 0.38 (0.17-0.88) .02 0.38 (0.16-0.90) .03 0.41 (0.15-1.17) .41
Diabetes mellitus 3.06 (1.77-5.31) <.0001 4.20 (2.60-6.80) <.0001 3.01 (1.78-5.09) <.0001 2.97 (1.59-5.54) .0007
Abbreviations: BMI, body mass index; HER2, human epidermal growth factor receptor 2; HR, hormone receptor.
exercise and nutrition programs or specialists. This can 
take a special effort on the part of the oncology team, but 
it is feasible,46,47 and for many patients, it may help them 
to understand the crucial importance of healthy lifestyles 
and engaging in daily exercise. The timing for these ac-
tions will be most impactful during the first 2 years after 
primary treatment when routine clinic visits provide an 
opportunity to reinforce the message and provide ongo-
ing support for behavioral change. Guidelines provided 
by the American Society of Clinical Oncology and oth-
ers support these actions as safe and important for most 
adults diagnosed with cancer.48,49 Again, it is essential for 
these conversations to be patient-centered and culturally 
appropriate50,51 and for people-first language to be used 
to avoid the stigma that many people with obesity per-
ceive in patient-clinician encounters.52,53
In conclusion, this study documents significant 
disparities between Black and White women with early 
breast cancer with regard to high rates of obesity as well as 
overall comorbidities and obesity-related comorbidities, 
many of which are independent of age and obesity itself, 
and it highlights the prevalence of competing risks that 
may complicate outcomes in breast cancer.
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